Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000410980 | SCV000489158 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-08-30 | criteria provided, single submitter | clinical testing | |
3DMed Clinical Laboratory Inc | RCV000677800 | SCV000803958 | pathogenic | Breast neoplasm | 2017-06-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005090656 | SCV005837710 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-06-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val1719Glyfs*11) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 31825140). ClinVar contains an entry for this variant (Variation ID: 371936). For these reasons, this variant has been classified as Pathogenic. |